Keyword Search Results for "acs"

Braunwald, E., Knatterud, G. L., Passamani, E. R., Robertson, T. L. Announcement of protocol change in thrombolysis in myocardial infarction trial Journal of the American College of Cardiology. 1987;9(2):467.

Braunwald, E., Knatterud, G. L., Passamani, E., Robertson, T. L., Solomon, R. Update from the Thrombolysis in Myocardial Infarction Trial Journal of the American College of Cardiology. 1987;10(4):970.

Mueller, H. S., Rao, A. K., Forman, S. A. Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator Journal of the American College of Cardiology. 1987;10(3):479-90. Abstract

Held, A. C., Gore, J. M., Paraskos, J., Pape, L. A., Ball, S. P., Corrao, J. M., Alpert, J. S. Impact of thrombolytic therapy on left ventricular mural thrombi in acute myocardial infarction American Journal of Cardiology. 1988;62(4):310-1.

Ong, L., Coromilas, J., Zimmerman, J. M., Green, S., Padmanabhan, V., Reiser, P., Bigger, J. T., Jr., Morrison, J. A physiologically based model of creatine kinase-MB release in reperfusion of acute myocardial infarction American Journal of Cardiology. 1989;64(1):5-Nov. Abstract

Rogers, W. J., Bourge, R. C., Papapietro, S. E., Wackers, F. J., Zaret, B. L., Forman, S., Dodge, H. T., Robertson, T. L., Passamani, E. R., Braunwald, E., et al., Variables predictive of good functional outcome following thrombolytic therapy in the Thrombolysis in Myocardial Infarction phase II (TIMI II) pilot study American journal of cardiology. 1989;63(9):503-12. Abstract

Sharkey, S. W., Bruneete, D. D., Ruiz, E., Hession, W. T., Wysham, D. G., Goldenberg, I. F., Hodges, M. An analysis of time delays preceding thrombolysis for acute myocardial infarction JAMA. 1989;262(22):3171-4. Abstract

Baim, D. S., Braunwald, E., Feit, F., Knatterud, G. L., Passamani, E. R., Robertson, T. L., Rogers, W. J., Solomon, R. E., Williams, D. O. The Thrombolysis in Myocardial Infarction (TIMI) Trial phase II: additional information and perspectives Journal of the American College of Cardiology. 1990;15(5):1188-92. Abstract

Rogers, W. J., Babb, J. D., Baim, D. S., Chesebro, J. H., Gore, J. M., Roberts, R., Williams, D. O., Frederick, M., Passamani, E. R., Braunwald, E. Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II Investigators Journal of the American College of Cardiology. 1991;17(5):1007-16. Abstract

Braunwald, E., Cannon, C. P., McCabe, C. H. An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point Circulation. 1992;86(2):683-7.

Braunwald, E., Knatterud, G., Passamani, E. The rt-PA versus streptokinase. Controversy--II Journal of the American College of Cardiology. 1992;19(5):1116-9.

Lehmann, K. G., Francis, C. K., Dodge, H. T. Mitral regurgitation in early myocardial infarction. Incidence, clinical detection, and prognostic implications. TIMI Study Group Annals of internal medicine. 1992;117(1):7-Oct. Abstract

Mueller, H. S., Cohen, L. S., Braunwald, E., Forman, S., Feit, F., Ross, A., Schweiger, M., Cabin, H., Davison, R., Miller, D., et al., Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II Circulation. 1992;85(4):1254-64. Abstract

Williams, D. O., Braunwald, E., Knatterud, G., Babb, J., Bresnahan, J., Greenberg, M. A., Raizner, A., Wasserman, A., Robertson, T., Ross, R. One-year results of the Thrombolysis in Myocardial Infarction investigation (TIMI) Phase II Trial Circulation. 1992;85(2):533-42. Abstract

Zaret, B. L., Wackers, F. J., Terrin, M. L., Ross, R., Weiss, M., Slater, J., Morrison, J., Bourge, R. C., Passamani, E., Knatterud, G., et al., Assessment of global and regional left ventricular performance at rest and during exercise after thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II Study American journal of cardiology. 1992;69(1):9-Jan. Abstract

Taylor, H. A., Chaitman, B. R., Rogers, W. J., Kern, M. J., Terrin, M. L., Aguirre, F. V., Sopko, G., McMahon, R., Ross, R. N., Bovill, E. C. Race and prognosis after myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial Circulation. 1993;88(4 Pt 1):1484-94. Abstract

Antman, E. M. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial Circulation. 1994;90:1624-30. Abstract

Becker, R. C., Tracy, R. P., Bovill, E. G., Corrao, J. M., Baker, S., Ball, S. P., Mann, K. G. Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest Journal of thrombosis and thrombolysis. 1994;1(1):101-107. Abstract

Becker, R. C., Tracy, R. P., Bovill, E. G., Mann, K. G., Ault, K. The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes. TIMI-III Thrombosis and Anticoagulation Group Coronary artery disease. 1994;5(4):339-45. Abstract

Flaker, G. C., Bartolozzi, J., Davis, V., McCabe, C., Cannon, C. P. Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction. TIMI 4 investigators. Thrombolysis in Myocardial Infarction Archives of internal medicine. 1994;154(13):1492-6. Abstract

Aguirre, F. V., Younis, L. T., Chaitman, B. R., Ross, A. M., McMahon, R. P., Kern, M. J., Berger, P. B., Sopko, G., Rogers, W. J., Shaw, L., et al., Early and 1-year clinical outcome of patients' evolving non-Q-wave versus Q-wave myocardial infarction after thrombolysis. Results from The TIMI II Study Circulation. 1995;91(10):2541-8. Abstract

Boisjolie, C. R., Sharkey, S. W., Cannon, C. P., Brunette, D., Haugland, J. M., Thatcher, J. L., Henry, T. D. Impact of a thrombolysis research trial on time to treatment for acute myocardial infarction in the emergency department American journal of cardiology. 1995;76(5):396-8. Abstract

Cannon, C. P. Hirudin in Acute Myocardial Infarction J Thromb Thrombolysis. 1995;1(3):259-267. Abstract

Cannon, C. P., Braunwald, E. Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty J Am Coll Cardiol. 1995;25(7 Suppl):30S-37S. Abstract

Mueller, Hiltrud S., Forman, Sandra A., Menegus, Mark A., Cohen, Lawrence S., Knatterud, Genell L., Braunwald, Eugene Prognostic significance of nonfatal reinfarction during 3-year follow-up: Results of the thrombolysis in myocardial infarction (TIMI) phase II clinical trial Journal of the American College of Cardiology. 1995;26(4):900-907.

Sloan, M. A., Price, T. R., Petito, C. K., Randall, A. M., Solomon, R. E., Terrin, M. L., Gore, J., Collen, D., Kleiman, N., Feit, F., et al., Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience Neurology. 1995;45(4):649-58. Abstract

Antman, E. M. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial Circulation. 1996;94:911-21. Abstract

Antman, E. M., Braunwald, E. Trials and tribulations of thrombin inhibition European heart journal. 1996;17(7):971-3.

Antman, E. M., Tanasijevic, M. J., Thompson, B., Schactman, M., McCabe, C. H., Cannon, C. P., Fischer, G. A., Fung, A. Y., Thompson, C., Wybenga, D., Braunwald, E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes New England journal of medicine. 1996;335(18):1342-9. Abstract

Antman, E. M. Another chapter of the antithrombin story has been written European heart journal. 1997;18(9):1365-7.

Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald E. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation. 1997;95:351-6. Abstract

Giugliano, R. P., Antman, E. M., Braunwald, E. Reexamination of the Thrombin Hypothesis: What We Have Learned from TIMI 9B and GUSTO IIb Journal of thrombosis and thrombolysis. 1997;4(4-Mar):321-323.

Borzak, S., Cannon, C. P., Kraft, P. L., Douthat, L., Becker, R. C., Palmeri, S. T., Henry, T., Hochman, J. S., Fuchs, J., Antman, E. M., McCabe, C., Braunwald, E. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia American journal of cardiology. 1998;81(6):678-81. Abstract

Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Circulation. 1998;97:340-9. Abstract

Kloner, R. A., Shook, T., Antman, E. M., Cannon, C. P., Przyklenk, K., Yoo, K., McCabe, C. H., Braunwald, E. Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B Circulation. 1998;97(11):1042-5. Abstract

Tracy, R. P., Kleiman, N. S., Thompson, B., Cannon, C. P., Bovill, E. G., Brown, R. G., Collen, D., Mahan, E., Mann, K. G., Rogers, W. J., Sopko, G., Stump, D. C., Williams, D. O., Zaret, B. L. Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial American heart journal. 1998;135(1):29-37. Abstract

Ault, K. A., Cannon, C. P., Mitchell, J., McCahan, J., Tracy, R. P., Novotny, W. F., Reimann, J. D., Braunwald, E. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction J Am Coll Cardiol. 1999;33(3):634-9. Abstract

Gibson CM, Ryan KA, Kelley M, Rizzo MJ, Mesley R, Murphy S, Swanson J, Marble SJ, Dodge JT, Giugliano RP, Cannon CP, Antman EM. Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. Am Heart J. 1999;137:1179-84. Abstract

Gibson, C. M., Cannon, C. P., Murphy, S. A., Adgey, A. A., Schweiger, M. J., Sequeira, R. F., Grollier, G., Fox, N. L., Berioli, S., Weaver, W. D., Van de Werf, F., Braunwald, E. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators Am J Cardiol. 1999;84(9):976-80. Abstract

Gibson, C. M., Ryan, K. A., Murphy, S. A., Mesley, R., Marble, S. J., Giugliano, R. P., Cannon, C. P., Antman, E. M., Braunwald, E. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction J Am Coll Cardiol. 1999;34(4):974-82. Abstract

Kizer, J. R., Cannon, C. P., McCabe, C. H., Mueller, H. S., Schweiger, M. J., Davis, V. G., Perritt, R., Antman, E. M. Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction American heart journal. 1999;137(1):79-92. Abstract

Scirica, B. M., Moliterno, D. J., Every, N. R., Anderson, H. V., Aguirre, F. V., Granger, C. B., Lambrew, C. T., Rabbani, L. E., Sapp, S. K., Booth, J. E., Ferguson, J. J., Cannon, C. P. Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry Am Heart J. 1999;138(6 Pt 1):1065-72. Abstract

Van de Werf, F., Cannon, C. P., Luyten, A., Houbracken, K., McCabe, C. H., Berioli, S., Bluhmki, E., Sarelin, H., Wang-Clow, F., Fox, N. L., Braunwald, E. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators Am Heart J. 1999;137(5):786-91. Abstract

Bozovich, G. E., Gurfinkel, E. P., Antman, E. M., McCabe, C. H., Mautner, B. Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time Am Heart J. 2000;140(4):637-42. Abstract

Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, Lopez-Sendon J, Toman J, Charlesworth A, Anders RJ, Alexander JC, Skene A, Braunwald E. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000;102:149-56. Abstract

Coulter, S. A., Cannon, C. P., Ault, K. A., Antman, E. M., Van de Werf, F., Adgey, A. A., Gibson, C. M., Giugliano, R. P., Mascelli, M. A., Scherer, J., Barnathan, E. S., Braunwald, E., Kleiman, N. S. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14 Circulation. 2000;101(23):2690-5. Abstract

Giugliano RP, McCabe CH, Sequeira RF, Frey MJ, Henry TD, Piana RN, Tamby JF, Jensen BK, Nicolas SB, Jennings LK, Wise RJ, Braunwald E. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. Am Heart J. 2000;140:81-93. Abstract

Holmes, M. B., Sobel, B. E., Cannon, C. P., Schneider, D. J. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction Am J Cardiol. 2000;85(4):491-3, A10. Abstract

Morrow, D. A., Rifai, N., Tanasijevic, M. J., Wybenga, D. R., de Lemos, J. A., Antman, E. M. Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy Clin Chem. 2000;46(4):453-60. Abstract

Cannon, C. P., McCabe, C. H., Wilcox, R. G., Bentley, J. H., Braunwald, E. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators Am J Cardiol. 2001;87(5):636-9, A10. Abstract

Gibson, C. M., de Lemos, J. A., Murphy, S. A., Marble, S. J., McCabe, C. H., Cannon, C. P., Antman, E. M., Braunwald, E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy Circulation. 2001;103(21):2550-4. Abstract

Giugliano, R. P., McCabe, C. H., Antman, E. M., Cannon, C. P., Van de Werf, F., Wilcox, R. G., Braunwald, E. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage Am Heart J. 2001;141(5):742-50. Abstract

O'Connor, F. F., Shields, D. C., Fitzgerald, A., Cannon, C. P., Braunwald, E., Fitzgerald, D. J. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes Blood. 2001;98(12):3256-60. Abstract

Schweiger, M. J., Cannon, C. P., Murphy, S. A., Gibson, C. M., Cook, J. R., Giugliano, R. P., Changezi, H. U., Antman, E. M., Braunwald, E. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience) Am J Cardiol. 2001;88(8):831-6. Abstract

Wang-Clow, F., Fox, N. L., Cannon, C. P., Gibson, C. M., Berioli, S., Bluhmki, E., Danays, T., Braunwald, E., Van De Werf, F., Stump, D. C. Determination of a weight-adjusted dose of TNK-tissue plasminogen activator Am Heart J. 2001;141(1):33-40. Abstract

de Lemos, J. A., Morrow, D. A., Bentley, J. H., Omland, T., Sabatine, M. S., McCabe, C. H., Hall, C., Cannon, C. P., Braunwald, E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes N Engl J Med. 2001;345(14):1014-21. Abstract

Brassard, J. A., Curtis, B. R., Cooper, R. A., Ferguson, J., Komocsar, W., Ehardt, M., Kupfer, S., Maurath, C., Swabb, E., Cannon, C. P., Aster, R. H. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology Thromb Haemost. 2002;88(6):892-7. Abstract

Brener, S. J., Murphy, S. A., Gibson, C. M., DiBattiste, P. M., Demopoulos, L. A., Cannon, C. P. Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes Am J Cardiol. 2002;90(6):631-3.

Cannon, C. P., McCabe, C. H., Belder, R., Breen, J., Braunwald, E. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial Am J Cardiol. 2002;89(7):860-1.

Deakin, C. D., Sado, D. M., Petley, G. W., Clewlow, F. Determining the optimal paddle force for external defibrillation American journal of cardiology. 2002;90(7):812-3.

Glaser, R., Herrmann, H. C., Murphy, S. A., Demopoulos, L. A., DiBattiste, P. M., Cannon, C. P., Braunwald, E. Benefit of an early invasive management strategy in women with acute coronary syndromes JAMA. 2002;288(24):3124-9.

Kenny, D., Muckian, C., Fitzgerald, D. J., Cannon, C. P., Shields, D. C. Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients J Thromb Thrombolysis. 2002;13(1):13-9. Abstract

Kloner, R. A., Poole, K., Shook, T., Przyklenk, K., Perritt, K., Cannon, C. P. Comparison of acute myocardial infarct size in patients > or =65 years versus < 65 years in the prethrombolytic period versus the thrombolytic period American journal of cardiology. 2002;89(11):1291-3.

Murphy, S. A., Gibson, C. M., Van de Werf, F., McCabe, C. H., Cannon, C. P. Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I) Am J Cardiol. 2002;90(1):51-4.

NA, NA Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data Lancet. 2002;359(9303):294-302. Abstract

Omland, T., de Lemos, J. A., Morrow, D. A., Antman, E. M., Cannon, C. P., Hall, C., Braunwald, E. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes Am J Cardiol. 2002;89(4):463-5.

Sabatine, M. S., McCabe, C. H., Morrow, D. A., Giugliano, R. P., de Lemos, J. A., Cohen, M., Antman, E. M., Braunwald, E. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge Am Heart J. 2002;143(6):966-70. Abstract

Sabatine, M. S., Morrow, D. A., Cannon, C. P., Murphy, S. A., Demopoulos, L. A., DiBattiste, P. M., McCabe, C. H., Braunwald, E., Gibson, C. M. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy J Am Coll Cardiol. 2002;40(10):1761-8.

Shields, D. C., Fitzgerald, A. P., O'Neill, P. A., Muckian, C., Kenny, D., Moran, B., Cannon, C. P., Byrne, C. E., Fitzgerald, D. J. The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists Pharmacogenomics J. 2002;2(3):182-90. Abstract

Cannon, C. P. The next step in cardiovascular protection Atheroscler Suppl. 2003;4(5):9-Mar. Abstract

Cannon, C. P. PROVE-IT TIMI 22 Study: potential effects on critical pathways for acute coronary syndrome Crit Pathw Cardiol. 2003;2(3):188-96.

Christenson, R. H., Leino, E. V., Giugliano, R. P., Bahr, R. D. Usefulness of prodromal unstable angina pectoris in predicting better survival and smaller infarct size in acute myocardial infarction (The InTIME-II Prodromal Symptoms Substudy) Am J Cardiol. 2003;92(5):598-600. Abstract

Januzzi, J. L., Jr., Sabatine, M. S., Wan, Y., Servoss, S. J., DiBattiste, P. M., Jang, Ik, Theroux, P. Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy Am J Cardiol. 2003;91(4):457-61.

Morrow, D. A., Rifai, N., Sabatine, M. S., Ayanian, S., Murphy, S. A., de Lemos, J. A., Braunwald, E., Cannon, C. P. Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes Clin Chem. 2003;49(8):1396-8.

Murphy, S. A., Dauterman, K., de Lemos, J. A., Kermgard, S., Antman, E. M., Braunwald, E., Gibson, C. M. Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the thrombolysis in myocardial infarction (TIMI) 14 trial Am Heart J. 2003;146(1):42-7. Abstract

Serrano, C. V., Jr., Nicolau, J. C., Venturinelli, M., Baracioli, L. M., Anders, R. J., Cannon, C. P., Ramires, J. A. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes Cardiovasc Drugs Ther. 2003;17(2):129-32. Abstract

de Lemos, J. A., Morrow, D. A., Sabatine, M. S., Murphy, S. A., Gibson, C. M., Antman, E. M., McCabe, C. H., Cannon, C. P., Braunwald, E. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes Circulation. 2003;107(5):690-5. Abstract

Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504.

Kovar, D., Cannon, C. P., Bentley, J. H., Charlesworth, A., Rogers, W. J. Does initial and delayed heart rate predict mortality in patients with acute coronary syndromes? Clin Cardiol. 2004;27(2):80-6. Abstract

Ray, K. K., Cannon, C. P. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology Curr Opin Lipidol. 2004;15(6):637-43. Abstract

Sabatine, M. S., Morrow, D. A., de Lemos, J. A., Omland, T., Desai, M. Y., Tanasijevic, M., Hall, C., McCabe, C. H., Braunwald, E. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia J Am Coll Cardiol. 2004;44(10):1988-95. Abstract

Cannon, C. P., Braunwald, E., McCabe, C. H., Grayston, J. T., Muhlestein, B., Giugliano, R. P., Cairns, R., Skene, A. M. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome N Engl J Med. 2005;352(16):1646-54.

Cantor, W. J., Goodman, S. G., Cannon, C. P., Murphy, S. A., Charlesworth, A., Braunwauld, E., Langer, A. Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial Am Heart J. 2005;149(2):275-83. Abstract

Dokainish, H., Pillai, M., Murphy, S. A., DiBattiste, P. M., Schweiger, M. J., Lotfi, A., Morrow, D. A., Cannon, C. P., Braunwald, E., Lakkis, N. Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy J Am Coll Cardiol. 2005;45(1):19-24.

Dupuis, J., Tardif, J. C., Rouleau, J. L., Ricci, J., Arnold, M., Lonn, E., Roux, R., Title, L. M., Amyot, R., Bonafede, N., Woo, A., Cannon, C. P. Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial) Am J Cardiol. 2005;96(9):1207-13. Abstract

Ferguson, J. J. Clopidogrel plus aspirin in patients with acute myocardial infarction treated with fibrinolytic therapy--CLARITY-TIMI 28 Future Cardiol. 2005;1(5):605-10. Abstract

Gomberg-Maitland, M., Murphy, S. A., Moliterno, D. J., Cannon, C. P. Are we appropriately triaging patients with unstable angina? Am Heart J. 2005;149(4):613-8. Abstract

Gurjeva, O. S., Bukhman, G., Murphy, S., Cannon, C. P. Treatment and outcomes of eastern Europeans with coronary syndromes in OPUS-TIMI 16 Int J Cardiol. 2005;100(1):101-7. Abstract

Ray, K. K., Cannon, C. P. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol. 2005;96(5A):54F-60F. Abstract

Ray, K. K., Cannon, C. P. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes J Am Coll Cardiol. 2005;46(8):1425-33. Abstract

Ray, K. K., Cannon, C. P., Cairns, R., Morrow, D. A., Rifai, N., Kirtane, A. J., McCabe, C. H., Skene, A. M., Gibson, C. M., Ridker, P. M., Braunwald, E. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial J Am Coll Cardiol. 2005;46(8):1417-24.

Ray, K. K., Cannon, C. P., McCabe, C. H., Cairns, R., Tonkin, A. M., Sacks, F. M., Jackson, G., Braunwald, E. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial J Am Coll Cardiol. 2005;46(8):1405-10.

Reid, I. R., Tonkin, A., Cannon, C. P. Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial--secondary analysis of a randomized controlled trial Bone. 2005;37(2):190-1.

Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., Braunwald, E. C-reactive protein levels and outcomes after statin therapy N Engl J Med. 2005;352(1):20-8.

Ridker, P. M., Morrow, D. A., Rose, L. M., Rifai, N., Cannon, C. P., Braunwald, E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial J Am Coll Cardiol. 2005;45(10):1644-8.

Sabatine, M. S., Morrow, D. A., Giugliano, R. P., Burton, P. B., Murphy, S. A., McCabe, C. H., Gibson, C. M., Braunwald, E. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes Circulation. 2005;111(16):2042-9. Abstract

Smith, C. S., Cannon, C. P., McCabe, C. H., Murphy, S. A., Bentley, J., Braunwald, E. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial Am Heart J. 2005;149(3):444-50. Abstract

Wiviott, S. D., Cannon, C. P., Morrow, D. A., Ray, K. K., Pfeffer, M. A., Braunwald, E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy J Am Coll Cardiol. 2005;46(8):1411-6.

Ahmed, S., Cannon, C. P., Murphy, S. A., Braunwald, E. Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial Eur Heart J. 2006;27(19):2323-9.

Bhadriraju, S., Ray, K. K., DeFranco, A. C., Barber, K., Bhadriraju, P., Murphy, S. A., Morrow, D. A., McCabe, C. H., Gibson, C. M., Cannon, C. P., Braunwald, E. Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial Am J Cardiol. 2006;97(11):1573-7. Abstract

Gibson, C. M., Kirtane, A. J., Morrow, D. A., Palabrica, T. M., Murphy, S. A., Stone, P. H., Scirica, B. M., Jennings, L. K., Herrmann, H. C., Cohen, D. J., McCabe, C. H., Braunwald, E. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30) Am Heart J. 2006;152(4):756-61.

Gibson, C. M., Morrow, D. A., Murphy, S. A., Palabrica, T. M., Jennings, L. K., Stone, P. H., Lui, H. H., Bulle, T., Lakkis, N., Kovach, R., Cohen, D. J., Fish, P., McCabe, C. H., Braunwald, E. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial J Am Coll Cardiol. 2006;47(12):2364-73.

Kirtane, A. J., Piazza, G., Murphy, S. A., Budiu, D., Morrow, D. A., Cohen, D. J., Peterson, E., Lakkis, N., Herrmann, H. C., Palabrica, T. M., Gibson, C. M. Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial J Am Coll Cardiol. 2006;47(12):2374-9.

Mega, J. L., Morrow, D. A., Cannon, C. P., Murphy, S., Cairns, R., Ridker, P. M., Braunwald, E. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy Journal of Thrombosis and Thrombolysis. 2006;22(1):71-76. Abstract

O'Donoghue, M., Morrow, D. A., Sabatine, M. S., Murphy, S. A., McCabe, C. H., Cannon, C. P., Braunwald, E. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial Circulation. 2006;113(14):1745-52.

O'Donoghue, M., de Lemos, J. A., Morrow, D. A., Murphy, S. A., Buros, J. L., Cannon, C. P., Sabatine, M. S. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes Circulation. 2006;114(6):550-7. Abstract

Ray, K. K., Bach, R. G., Cannon, C. P., Cairns, R., Kirtane, A. J., Wiviott, S. D., McCabe, C. H., Braunwald, E., Gibson, C. M. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS Eur Heart J. 2006;27(19):2310-6.

Ray, K. K., Morrow, D. A., Shui, A., Rifai, N., Cannon, C. P. Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22) Am J Cardiol. 2006;98(7):861-5. Abstract

Scirica, B. M., Cannon, C. P., Cooper, R., Aster, R. H., Brassard, J., McCabe, C. H., Charlesworth, A., Skene, A. M., Braunwald, E. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial J Thromb Thrombolysis. 2006;22(2):95-102. Abstract

Scirica, B. M., Morrow, D. A., Cannon, C. P., Ray, K. K., Sabatine, M. S., Jarolim, P., Shui, A., McCabe, C. H., Braunwald, E. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study J Am Coll Cardiol. 2006;47(11):2326-31.

Smith, E. E., Cannon, C. P., Murphy, S., Feske, S. K., Schwamm, L. H. Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study Am Heart J. 2006;151(2):338-44. Abstract

Wiviott, S. D., Antman, E. M., Gibson, C. M., Montalescot, G., Riesmeyer, J., Weerakkody, G., Winters, K. J., Warmke, J. W., McCabe, C. H., Braunwald, E. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) Am Heart J. 2006;152(4):627-35. Abstract

Wiviott, S. D., Cannon, C. P. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy Curr Opin Lipidol. 2006;17(6):626-30. Abstract

Wiviott, S. D., de Lemos, J. A., Cannon, C. P., Blazing, M., Murphy, S. A., McCabe, C. H., Califf, R., Braunwald, E. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22 Circulation. 2006;113(11):1406-14. Abstract

Cannon, C. P. Clopidogrel: who, when, and how? Rev Cardiovasc Med. 2007;8 Suppl 3(NA):S27-34. Abstract

Murphy, S. A., Cannon, C. P., Wiviott, S. D., de Lemos, J. A., Blazing, M. A., McCabe, C. H., Califf, R. M., Braunwald, E. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials) Am J Cardiol. 2007;100(7):1047-51. Abstract

Ray, K. K., Cannon, C. P., Morrow, D. A., Kirtane, A. J., Buros, J., Rifai, N., McCabe, C. H., Gibson, C. M., Braunwald, E. Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18 Eur Heart J. 2007;28(7):806-13. Abstract

Ray, K. K., Morrow, D. A., Sabatine, M. S., Shui, A., Rifai, N., Cannon, C. P., Braunwald, E. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome Circulation. 2007;115(24):3071-8.

Schreiner, G. C., Laine, L., Murphy, S. A., Cannon, C. P. Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed Crit Pathw Cardiol. 2007;6(4):169-72. Abstract

Scirica, B. M., Morrow, D. A., Cannon, C. P., de Lemos, J. A., Murphy, S., Sabatine, M. S., Wiviott, S. D., Rifai, N., McCabe, C. H., Braunwald, E., Thrombolysis in Myocardial Infarction Study, Group Clinical application of C-reactive protein across the spectrum of acute coronary syndromes Clin Chem. 2007;53(10):1800-7. Abstract

Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F. J., Ardissino, D., De Servi, S., Murphy, S. A., Riesmeyer, J., Weerakkody, G., Gibson, C. M., Antman, E. M. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med. 2007;357(20):2001-15. Abstract

Yeh, R. W., Wiviott, S. D., Giugliano, R. P., Morrow, D. A., Shui, A., Qin, J., Scirica, B., Bradner, J. E., Jang, I. K., Gibson, C. M., Antman, E. M. Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes Am J Cardiol. 2007;100(12):1734-8. Abstract

de Lemos, J. A., Morrow, D. A., Blazing, M. A., Jarolim, P., Wiviott, S. D., Sabatine, M. S., Califf, R. M., Braunwald, E. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial J Am Coll Cardiol. 2007;50(22):2117-24. Abstract

Antman, E. M., Wiviott, S. D., Murphy, S. A., Voitk, J., Hasin, Y., Widimsky, P., Chandna, H., Macias, W., McCabe, C. H., Braunwald, E. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis J Am Coll Cardiol. 2008;51(21):2028-33. Abstract

Braunwald, E., Angiolillo, D., Bates, E., Berger, P. B., Bhatt, D., Cannon, C. P., Furman, M. I., Gurbel, P., Michelson, A. D., Peterson, E., Wiviott, S. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes Clin Cardiol. 2008;31(3 Suppl 1):I2-9. Abstract

Brilakis, E. S., de Lemos, J. A., Cannon, C. P., Wiviott, S. D., Murphy, S. A., Morrow, D. A., Sabatine, M. S., Banerjee, S., Blazing, M. A., Califf, R. M., Braunwald, E. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials) Am J Cardiol. 2008;102(5):552-8. Abstract

Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156:826-32. Abstract

Cannon, C. P., Greenberg, B. H. Risk stratification and prognostic factors in the post-myocardial infarction patient Am J Cardiol. 2008;102(5A):13G-20G. Abstract

Giraldez, R. R., Giugliano, R. P., Mohanavelu, S., Murphy, S. A., McCabe, C. H., Cannon, C. P., Braunwald, E. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis J Am Coll Cardiol. 2008;52(11):914-20.

Iakoubova, O. A., Sabatine, M. S., Rowland, C. M., Tong, C. H., Catanese, J. J., Ranade, K., Simonsen, K. L., Kirchgessner, T. G., Cannon, C. P., Devlin, J. J., Braunwald, E. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study J Am Coll Cardiol. 2008;51(4):449-55.

Lotfi, A., Schweiger, M. J., Giugliano, G. R., Murphy, S. A., Cannon, C. P. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis Am Heart J. 2008;155(5):954-8.

Mega, J. L., Morrow, D. A., de Lemos, J. A., Mohanavelu, S., Cannon, C. P., Sabatine, M. S. Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes J Am Coll Cardiol. 2008;51(25):2422-9. Abstract

Miller, M., Cannon, C. P., Murphy, S. A., Qin, J., Ray, K. K., Braunwald, E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial J Am Coll Cardiol. 2008;51(7):724-30.

Morrow, D. A., Wang, Y., Croce, K., Sakuma, M., Sabatine, M. S., Gao, H., Pradhan, A. D., Healy, A. M., Buros, J., McCabe, C. H., Libby, P., Cannon, C. P., Braunwald, E., Simon, D. I. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial Am Heart J. 2008;155(1):49-55.

Olenchock, B. A., Wiviott, S. D., Murphy, S. A., Cannon, C. P., Rifai, N., Braunwald, E., Morrow, D. A. Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16 J Thromb Thrombolysis. 2008;26(2):79-84. Abstract

Wiviott, S. D., Braunwald, E., Angiolillo, D. J., Meisel, S., Dalby, A. J., Verheugt, F. W., Goodman, S. G., Corbalan, R., Purdy, D. A., Murphy, S. A., McCabe, C. H., Antman, E. M. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38 Circulation. 2008;118(16):1626-36. Abstract

Wiviott, S. D., Braunwald, E., McCabe, C. H., Horvath, I., Keltai, M., Herrman, J. P., Van de Werf, F., Downey, W. E., Scirica, B. M., Murphy, S. A., Antman, E. M. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial Lancet. 2008;371(9621):1353-63. Abstract

Wiviott, S. D., Braunwald, E., Murphy, S. A., Antman, E. M. A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38 Am J Cardiol. 2008;101(9):1367-70.

Gibson, C. M., Mega, J. L., Jennings, L. K., Mohanavelu, S., Misselwitz, F., Plotnikov, A., Sun, X., Zolynas, R., Braunwald, E. Effect of Rivaroxaban on Markers of Coagulation in Patients With Acute Coronary Syndromes: An ATLAS ACS-TIMI 46 Substudy Circulation. 2009;120(18):S1035-S1035.

Gibson, C. M., Pride, Y. B., Buros, J. L., Ciaglo, L. N., Morrow, D. A., Scirica, B. M., Stone, P. H. Timing and duration of myocardial ischemia on Holter monitoring following percutaneous coronary intervention and their association with clinical outcomes (a PROTECT-TIMI 30 Substudy Analysis) Am J Cardiol. 2009;104(1):36-40.

Gibson, C. M., Pride, Y. B., Hochberg, C. P., Sloan, S., Sabatine, M. S., Cannon, C. P. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy J Am Coll Cardiol. 2009;54(24):2290-5.

Giugliano, R. P., White, J. A., Bode, C., Armstrong, P. W., Montalescot, G., Lewis, B. S., van 't Hof, A., Berdan, L. G., Lee, K. L., Strony, J. T., Hildemann, S., Veltri, E., Van de Werf, F., Braunwald, E., Harrington, R. A., Califf, R. M., Newby, L. K. Early versus delayed, provisional eptifibatide in acute coronary syndromes N Engl J Med. 2009;360(21):2176-90. Abstract

Mega, J. L., Braunwald, E., Lee, M., Misselwitz, F., Mohanavelu, S., Notani, R., Peters, G., Gibson, C. M. Cessation of Rivaroxaban in Post-ACS Patients is Not Associated With Clinical Evidence of Rebound Hypercoagulability: An ATLAS ACS-TIMI 46 Substudy Circulation. 2009;120(18):S1002-S1002.

Mega, J. L., Braunwald, E., Mohanavelu, S., Burton, P., Poulter, R., Misselwitz, F., Hricak, V., Barnathan, E. S., Bordes, P., Witkowski, A., Markov, V., Oppenheimer, L., Gibson, C. M. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Lancet. 2009;374(9683):29-38. Abstract

Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W. L., Braunwald, E., Sabatine, M. S. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation. 2009;119(19):2553-60. Abstract

Mega, J. L., Morrow, D. A., Brown, A., Cannon, C. P., Sabatine, M. S. Identification of genetic variants associated with response to statin therapy Arteriosclerosis, thrombosis, and vascular biology. 2009;29(9):1310-5. Abstract

Morrow, D. A., Scirica, B. M., Chaitman, B. R., McGuire, D. K., Murphy, S. A., Karwatowska-Prokopczuk, E., McCabe, C. H., Braunwald, E. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial Circulation. 2009;119(15):2032-9. Abstract

Morrow, D. A., Wiviott, S. D., White, H. D., Nicolau, J. C., Bramucci, E., Murphy, S. A., Bonaca, M. P., Ruff, C. T., Scirica, B. M., McCabe, C. H., Antman, E. M., Braunwald, E. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction Circulation. 2009;119(21):2758-64. Abstract

Murphy, S. A., Cannon, C. P., Wiviott, S. D., McCabe, C. H., Braunwald, E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial Journal of the American College of Cardiology. 2009;54(25):2358-62. Abstract

O'Donoghue, M., Antman, E. M., Braunwald, E., Murphy, S. A., Steg, P. G., Finkelstein, A., Penny, W. F., Fridrich, V., McCabe, C. H., Sabatine, M. S., Wiviott, S. D. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis Journal of the American College of Cardiology. 2009;54(8):678-85. Abstract

Olenchock, B. A., Fonarow, G. G., Pan, W., Hernandez, A., Cannon, C. P. Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes Am J Cardiol. 2009;103(3):295-300. Abstract

Pride, Y. B., Wiviott, S. D., Buros, J. L., Zorkun, C., Tariq, M. U., Antman, E. M., Braunwald, E., Gibson, C. M. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy American heart journal. 2009;158(3):e21-6. Abstract

Ray, K. K., Cannon, C. P., Cairns, R., Morrow, D. A., Ridker, P. M., Braunwald, E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22 Arteriosclerosis, thrombosis, and vascular biology. 2009;29(3):424-30. Abstract

Sabatine, M. S., Antman, E. M., Widimsky, P., Ebrahim, I. O., Kiss, R. G., Saaiman, A., Polasek, R., Contant, C. F., McCabe, C. H., Braunwald, E. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial Lancet. 2009;374(9692):787-95. Abstract

Scirica, B. M., Cannon, C. P., Sabatine, M. S., Jarolim, P., Sloane, S., Rifai, N., Braunwald, E., Morrow, D. A. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death Clin Chem. 2009;55(2):265-73.

Tung, P., Wiviott, S. D., Cannon, C. P., Murphy, S. A., McCabe, C. H., Gibson, C. M. Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study) Am J Cardiol. 2009;103(8):1056-60.

Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., Mahaffey, K. W., Scirica, B. M., Skene, A., Steg, P. G., Storey, R. F., Harrington, R. A., Plato Investigators, Freij, A., Thorsen, M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med. 2009;361(11):1045-57. Abstract

Acharjee, S., Cannon, C. P. Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers Crit Pathw Cardiol. 2010;9(3):156-9. Abstract

Bangalore, S., Qin, J., Sloan, S., Murphy, S. A., Cannon, C. P. What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial Circulation. 2010;122(21):2142-51. Abstract

Califf, R. M., Lokhnygina, Y., Cannon, C. P., Stepanavage, M. E., McCabe, C. H., Musliner, T. A., Pasternak, R. C., Blazing, M. A., Giugliano, R. P., Harrington, R. A., Braunwald, E. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design Am Heart J. 2010;159(5):705-9.

Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375:283-93. Abstract

Fox, C. S., Muntner, P., Chen, A. Y., Alexander, K. P., Roe, M. T., Cannon, C. P., Saucedo, J. F., Kontos, M. C., Wiviott, S. D., Acute Coronary, Treatment, Intervention Outcomes Network, registry Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry Circulation. 2010;121(3):357-65. Abstract

James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, Maya J, Nicolau JC, Spinar J, Storey RF, Stevens SR, Wallentin L; PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Euro Heart J. 2010;31:3006-3016. Abstract

Khera, A. V., Wolfe, M. L., Cannon, C. P., Qin, J., Rader, D. J. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study) Am J Cardiol. 2010;106(4):451-6. Abstract

Mahoney, E. M., Wang, K., Arnold, S. V., Proskorovsky, I., Wiviott, S., Antman, E., Braunwald, E., Cohen, D. J. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38 Circulation. 2010;121(1):71-9. Abstract

Maree, A. O., Vangjeli, C., Jneid, H., Ryan, J., Cox, D., Cannon, C. P., Shields, D. C., Fitzgerald, D. J. G-protein beta3 subunit polymorphism and bleeding in the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction 16 trial J Thromb Haemost. 2010;8(5):934-41. Abstract

Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Walker, J. R., Simon, T., Antman, E. M., Braunwald, E., Sabatine, M. S. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet. 2010;376(9749):1312-9. Abstract

Mega, J. L., Simon, T., Collet, J. P., Anderson, J. L., Antman, E. M., Bliden, K., Cannon, C. P., Danchin, N., Giusti, B., Gurbel, P., Horne, B. D., Hulot, J. S., Kastrati, A., Montalescot, G., Neumann, F. J., Shen, L., Sibbing, D., Steg, P. G., Trenk, D., Wiviott, S. D., Sabatine, M. S. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA. 2010;304(16):1821-30. Abstract

Melloni, Chiara, James, Stefan K., White, Jennifer A., Giugliano, Robert P., Harrington, Robert A., Huber, Kurt, Armstrong, Paul W., Califf, Robert M., Van de Werf, Frans, Montalescot, Gilles, Newby, L. Kristin Safety and Efficacy of Adjusted-Dose Eptifibatide in Patients with Acute Coronary Syndromes and Reduced Renal Function J Am Coll Cardiol. 2010;55(10s1):A102.E957-A102.E957.

Pride, Y. B., Tung, P., Mohanavelu, S., Zorkun, C., Wiviott, S. D., Antman, E. M., Giugliano, R., Braunwald, E., Gibson, C. M. Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy JACC Cardiovascular interventions. 2010;3(8):806-11. Abstract

Ray, K. K., Nazer, B., Cairns, R., Michael Gibson, C., Cannon, C. P. Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes J Thromb Thrombolysis. 2010;30(1):3-Oct. Abstract

Scirica, B. M., Morrow, D. A., Bode, C., Ruzyllo, W., Ruda, M., Oude Ophuis, A. J., Lopez-Sendon, J., Swedberg, K., Ogorek, M., Rifai, N., Lukashevich, V., Maboudian, M., Cannon, C. P., McCabe, C. H., Braunwald, E. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial European heart journal. 2010;31(16):1993-2005. Abstract

Abtahian, F., Olenchock, B., Ou, F. S., Kontos, M. C., Saucedo, J. F., Scirica, B. M., Desai, N., Peterson, E., Roe, M., Cannon, C. P., Wiviott, S. D. Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry) Am J Cardiol. 2011;107(10):1441-6. Abstract

Bonaca, M. P., Morrow, D. A., Braunwald, E., Cannon, C. P., Jiang, S., Breher, S., Sabatine, M. S., Kempf, T., Wallentin, L., Wollert, K. C. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22 Arteriosclerosis, thrombosis, and vascular biology. 2011;31(1):203-10. Abstract

Bonaca, M. P., Ruff, C. T., Grandin, E. W., Murphy, S. A., Jarolim, P., Conrad, M. J., Vora, A., Sabatine, M. S., Braunwald, E., Morrow, D. A. Evaluation of the Diagnostic Performance of an Investigational Ultra-Sensitive Assay for CARDIAC TROPONIN I Journal of the American College of Cardiology. 2011;57(14):E1018-E1018.

Bonaca, Marc P., Braunwald, Eugene, Murphy, Sabina A., Miller, Debra, Herrman, Jp R., Gottlieb, Shmuel, Menozzi, Alberto, McCabe, Carolyn H., Antman, Elliot M., Wiviott, Stephen W. LONG-TERM THIENOPYRIDINE THERAPY AND OUTCOMES IN PATIENTS WITH ACS TREATED WITH CORONARY STENTING: THE PRIMARY RESULTS OF THE TIMI-38 CORONARY STENT REGISTRY Journal of the American College of Cardiology. 2011;57(14, Supplement):E906.

Gibson, C. M., Mega, J. L., Burton, P., Goto, S., Verheugt, F., Bode, C., Plotnikov, A., Sun, X., Cook-Bruns, N., Braunwald, E. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome American heart journal. 2011;161(5):815-821 e6. Abstract

Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, Harrington RA, Horrow J, Husted S, James SK, Mahaffey KW, Nicolau JC, Scirica BM, Storey RF, Vintila M, Ycas J, Wallentin L. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57:672-84. Abstract

James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF, Stevens S, Wallentin L, Harrington RA; PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. Brit Med J. 2011;342:d3527. Abstract

Kunadian, V., Pride, Y. B., Buros, J. L., Ciaglo, L. N., Morrow, D. A., Gibson, C. M. Coronary flow reserve varies depending upon the location within the artery it is assessed and the TIMI myocardial perfusion grade: a PROTECT TIMI-30 analysis J Thromb Thrombolysis. 2011;32(4):448-52. Abstract

Kunadian, V., Zorkun, C., James, S., Wu, J. H., Muhammad, A., Storey, R., Steg, P. G., Katus, H., Emanuelsson, H., Horrow, J., Maya, J., Wallentin, L., Harrington, R., Gibson, C. M. ANGIOGRAPHIC OUTCOMES IN THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL Journal of the American College of Cardiology. 2011;57(14):E946-E946.

Mega JL, Hochholzer W, Frelinger AL 3rd, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. J Am Med Assoc. 2011;306:2221-8. Abstract

Nazer, B., Ray, K. K., Sloan, S., Scirica, B., Morrow, D. A., Cannon, C. P., Braunwald, E. Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome European heart journal. 2011;32(11):1390-7. Abstract

O'Donoghue, M. L., Bhatt, D. L., Wiviott, S. D., Goodman, S. G., Fitzgerald, D. J., Angiolillo, D. J., Goto, S., Montalescot, G., Zeymer, U., Aylward, P. E., Guetta, V., Dudek, D., Ziecina, R., Contant, C. F., Flather, M. D., Lancelot-Acs Investigators Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial Circulation. 2011;123(17):1843-53. Abstract

Ruff, C. T., Braunwald, E. The evolving epidemiology of acute coronary syndromes Nat Rev Cardiol. 2011;8(3):140-7. Abstract

Scirica BM, Cannon CP, Emanuelsson H, Michelson EL, Harrington RA, Husted S, James S, Katus H, Pais P, Raev D, Spinar J, Steg PG, Storey RF, Wallentin L; PLATO Investigators. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol. 2011;57:1908-16. Abstract

Syed, Z., Stultz, C. M., Scirica, B. M., Guttag, J. V. Computationally generated cardiac biomarkers for risk stratification after acute coronary syndrome Sci Transl Med. 2011;3(102):102ra95. Abstract

Truong, Q. A., Murphy, S. A., McCabe, C. H., Armani, A., Cannon, C. P. Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22 Circ Cardiovasc Qual Outcomes. 2011;4(3):328-36. Abstract

Udell, J. A., Morrow, D. A., Contant, C. F., Brunel, P. C., Prescott, M. F., Braunwald, E., Scirica, B. M., Avant Garde-Timi Investigators Inhibition of Renin-Angiotensin System (RAS) Reduces the Rise in Plasma Aldosterone Levels After Acute Coronary Syndromes in Patients with Preserved Left Ventricular Function: Insight From AVANT GARDE-TIMI 43 Trial Circulation. 2011;124(21):NA.

Wilson, S. R., Sabatine, M. S., Wiviott, S. D., Ray, K. K., De Lemos, J. A., Zhou, S., Rifai, N., Cannon, C. P., Morrow, D. A., Timi Study Group Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Am Heart J. 2011;161(6):1147-55 e1. Abstract

Wiviott, S. D., Desai, N., Murphy, S. A., Musumeci, G., Ragosta, M., Antman, E. M., Braunwald, E. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies Am J Cardiol. 2011;108(7):905-11. Abstract

Bui, A. H., Bonaca, M. P., Sabatine, M. S., Ray, K. K., Rifai, N., Cannon, C. P., Morrow, D. A. Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial J Thromb Thrombolysis. 2012;34(2):222-8. Abstract

Chia, C. C., Rubinfeld, I., Scirica, B. M., McMillan, S., Gurm, H. S., Syed, Z. Looking beyond historical patient outcomes to improve clinical models Sci Transl Med. 2012;4(131):131ra49. Abstract

Gibson, C. Michael, Levitan, Bennett, Murphy, Sabina A, Yuan, Zhong, Chakrabarti, Anjan, Lee, Michael, Mega, Jessica, Braunwald, Eugene Abstract 13152: A Net Clinical Outcome Analysis Comparing Fatal or Irreversible Ischemic and Bleeding Events in ATLAS ACS 2 - TIMI 51 Circulation. 2012;126(21 Supplement):A13152.

Grandin, E. W., Jarolim, P., Murphy, S. A., Ritterova, L., Cannon, C. P., Braunwald, E., Morrow, D. A. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22 Clinical chemistry. 2012;58(1):267-73. Abstract

Hall, Hurst M, Enriquez, Jonathan R, de Lemos, James A, Desai, Nihar, Peng, S. Andrew, Alexander, Karen P, Roe, Matthew T, McGuire, Darren K, Wiviott, Stephen D, Das, Sandeep R Abstract 12693: Patterns of Discharge Aspirin Dosing in 213,344 U.S. Patients after Acute Myocardial Infarction: Results from the NCDR Circulation. 2012;126(21 Supplement):A12693.

Hoffmann, U., Truong, Q. A., Schoenfeld, D. A., Chou, E. T., Woodard, P. K., Nagurney, J. T., Pope, J. H., Hauser, T. H., White, C. S., Weiner, S. G., Kalanjian, S., Mullins, M. E., Mikati, I., Peacock, W. F., Zakroysky, P., Hayden, D., Goehler, A., Lee, H., Gazelle, G. S., Wiviott, S. D., Fleg, J. L., Udelson, J. E., Romicat-Ii Investigators Coronary CT angiography versus standard evaluation in acute chest pain N Engl J Med. 2012;367(4):299-308. Abstract

Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, Lopes RD, Morais J, Mahaffey KW, Bach RG, Wojdyla D, Wallentin L; PLATO study group. Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial. Circ Cardiovasc Qual Outcomes. 2012;5:680-688. Abstract

James SK, Storey RF, Khurmi NS, Husted S, Keltai M, Mahaffey KW, Maya J, Morais J, Lopes RD, Nicolau JC, Pais P, Raev D, Lopez-Sendon JL, Stevens SR, Becker RC; PLATO Study Group. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack. Circulation. 2012;125:2914-2921. Abstract

Kulik, Alexander, Desai, Nihar R., Shrank, William H., Antman, Elliott M., Avorn, Jerry, Glynn, Robert J., Levin, Raisa, Choudhry, Niteesh K. Abstract 13548: Full Prescription Coverage versus Usual Prescription Coverage after Coronary Artery Bypass Graft Surgery for Recent Myocardial Infarction: Analysis from the MI FREEE Randomized Trial Circulation. 2012;126(21 Supplement):A13548.

Kumbhani, Dharam J., Bavry, Anthony A., Bhatt, Deepak L. Abstract 17864: Role of Aspiration and Mechanical Thrombectomy in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty: An Updated Meta-Analysis of Randomized Trials Circulation. 2012;126(21 Supplement):A17864.

Kumbhani, Dharam J., Fonarow, Gregg C., Cannon, Christopher P., Hernandez, Adrian F., Peterson, Eric D., Peacock, W. F., Laskey, Warren K., Grau-Sepulveda, Maria, Schwamm, Lee H., Bhatt, Deepak L. Abstract 17901: A Comparison of Temporal Trends in In-hospital Adherence to Secondary Prevention Measures Among Patients Undergoing Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention or No Intervention: Insights From the GWTG-CAD Circulation. 2012;126(21 Supplement):A17901.

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19. Abstract

Mega, Jessica L, Braunwald, Eugene, Wiviott, Stephen D, Murphy, Sabina, Plotnikov, Alexei, Gotcheva, Nina, Ruda, Mikhail, Gibson, C. Michael Abstract 16014: Evaluation of Cardiac Events in ATLAS ACS 2-TIMI 51 Circulation. 2012;126(21 Supplement):A16014.

Pride, Yuri, Mohanavelu, Satishkumar, Mega, Jessica, Braunwald, Eugene, Gibson, C. Michael Abstract 9944: Temporal Relationship Between Major Hemorrhagic Events and Mortality among Patients with Recent Acute Coronary Syndrome: Insights from ATLAS ACS 2-TIMI 51 Circulation. 2012;126(21 Supplement):A9944.

Roe, M. T., Armstrong, P. W., Fox, K. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., Ardissino, D., Nicolau, J. C., Boden, W. E., Gurbel, P. A., Ruzyllo, W., Dalby, A. J., McGuire, D. K., Leiva-Pons, J. L., Parkhomenko, A., Gottlieb, S., Topacio, G. O., Hamm, C., Pavlides, G., Goudev, A. R., Oto, A., Tseng, C. D., Merkely, B., Gasparovic, V., Corbalan, R., Cinteza, M., McLendon, R. C., Winters, K. J., Brown, E. B., Lokhnygina, Y., Aylward, P. E., Huber, K., Hochman, J. S., Ohman, E. M., Trilogy Acs Investigators Prasugrel versus clopidogrel for acute coronary syndromes without revascularization N Engl J Med. 2012;367(14):1297-309. Abstract

Ruff, C. T., Giugliano, R. P., Antman, E. M., Murphy, S. A., Lotan, C., Heuer, H., Merkely, B., Baracioli, L., Schersten, F., Seabro-Gomes, R., Braunwald, E., Wiviott, S. D. Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world Int J Cardiol. 2012;155(3):424-9. Abstract

Sarma, Amy, Wiviott, Stephen D, Antman, Elliott, Mega, Jessica L, Murphy, Sabina A, Hoffman, Elaine, Sabatine, Marc S, O'Donoghue, Michelle L Abstract 17455: Pharmacodynamic Response to Clopidogrel in Men versus Women: Insights from the PRINCIPLE-TIMI 44 Trial Circulation. 2012;126(21 Supplement):A17455.

Steen, Dylan L, Cannon, Christopher P, Lele, Suhas, Rajapurkar, Mohan, Mukhopadhyay, Banibrata, Scirica, Benjamin M, Morrow, David A Abstract 18754: Prognostic Evaluation of Catalytic Iron in Patients with Acute Coronary Syndromes: Observations from OPUS-TIMI 16 Circulation. 2012;126(21 Supplement):A18754.

Steg, P. G., Mehta, S. R., Pollack, C. V., Jr., Bode, C., Gaudin, C., Fanouillere, K., Moryusef, A., Wiviott, S. D., Sabatine, M. S. Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy Am Heart J. 2012;164(6):817-24 e13. Abstract

Varenhorst C, Alström U, Scirica BM, Hogue CW, Åsenblad N, Storey RF, Steg PG, Horrow J, Mahaffey KW, Becker RC, James S, Cannon CP, Brandrup-Wognsen G, Wallentin L, Held C. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2012;60:1623-30. Abstract

Vora, A. N., Bonaca, M. P., Ruff, C. T., Jarolim, P., Murphy, S., Croce, K., Sabatine, M. S., Simon, D. I., Morrow, D. A. Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain J Thromb Thrombolysis. 2012;34(2):229-34. Abstract

Anderson, M. L., Peterson, E. D., Peng, S. A., Wang, T. Y., Ohman, E. M., Bhatt, D. L., Saucedo, J. F., Roe, M. T. Differences in the Profile, Treatment, and Prognosis of Patients With Cardiogenic Shock by Myocardial Infarction Classification: A Report From NCDR Circ Cardiovasc Qual Outcomes. 2013;6(6):708-15. Abstract

Bansilal S, Bonaca MP, Sabatine MS. Ticagrelor for acute coronary syndromes. Expert Rev Cardiovasc Ther. 2013;11:1473-84. Abstract

Bansilal, S., Wiviott, S., Becker, R., Harrington, R., Himmelmann, A., Neely, B., Husted, S., Storey, R., Steg, P., Katus, H., James, S., Wallentin, L., Cannon, C., Timi Study Group The Efficacy and Safety of Ticagrelor as Compared to Clopidogrel, with and without a Glycoprotein iib/iiia Inhibitor in Patients with Acute Coronary Syndromes Undergoin Percutaneous Intervention: A PLATO (Study of Platelet Inhibition and Patient Outcomes) Analysis Journal of the American College of Cardiology. 2013;61(10):A460.

Bhatt, D. L., Stone, G. W., Mahaffey, K. W., Gibson, C. M., Steg, P. G., Hamm, C. W., Price, M. J., Leonardi, S., Gallup, D., Bramucci, E., Radke, P. W., Widimsky, P., Tousek, F., Tauth, J., Spriggs, D., McLaurin, B. T., Angiolillo, D. J., Genereux, P., Liu, T., Prats, J., Todd, M., Skerjanec, S., White, H. D., Harrington, R. A., Champion Phoenix Investigators Effect of platelet inhibition with cangrelor during PCI on ischemic events N Engl J Med. 2013;368(14):1303-13. Abstract

Braunwald, E. Cardiovascular science: opportunities for translating research into improved care J Clin Invest. 2013;123(1):10-Jun. Abstract

Cavender, M. A., Braunwald, E. B., Gibson, C. M., Wiviott, S., Murphy, S., Amuchastegui, A., Ophuis, A. J, van Hessen, M, Mega, J. L., Timi Study Group Rivaroxaban Reduces Spontaneous and Large Myocardial Infarctions: findings from the ATLAS ACS 2 - TIMI 51 Trial Journal of the American College of Cardiology. 2013;61(10):A1.

Chan, P. S., Rao, S. V., Bhatt, D. L., Rumsfeld, J. S., Gurm, H. S., Nallamothu, B. K., Cavender, M. A., Kennedy, K., Spertus, J. A. Patient and Hospital Characteristics Associated with Inappropriate Percutaneous Coronary Interventions J Am Coll Cardiol. 2013;NA(NA):NA. Abstract

Desai, N. Variability in Response: Patterns in Prescribming Antiplatelet Therapy after CYP2C19 Genotyping among Patients with ACS and PCI Journal of the American College of Cardiology. 2013;61(10):A39.

Feres, F., Costa, R. A., Abizaid, A., Leon, M. B., Marin-Neto, J. A., Botelho, R. V., King, S. B., 3rd, Negoita, M., Liu, M., de Paula, J. E., Mangione, J. A., Meireles, G. X., Castello, H. J., Jr., Nicolela, E. L., Jr., Perin, M. A., Devito, F. S., Labrunie, A., Salvadori, D., Jr., Gusmao, M., Staico, R., Costa, J. R., Jr., de Castro, J. P., Abizaid, A. S., Bhatt, D. L., for the, Optimize Trial Investigators Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents: The OPTIMIZE Randomized Trial JAMA. 2013;NA(NA):NA. Abstract

Geller, B. J., Mega, J. L., Morrow, D. A., Guo, J., Hoffman, E. B., Gibson, C. M., Ruff, C. T. Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial J Thromb Thrombolysis. 2013;NA(NA):NA. Abstract

Gibson, C. M., Chakrabarti, A. K., Mega, J., Bode, C., Bassand, J. P., Verheugt, F. W., Bhatt, D. L., Goto, S., Cohen, M., Mohanavelu, S., Burton, P., Stone, G., Braunwald, E., Atlas-Acs Timi Investigators Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51 J Am Coll Cardiol. 2013;62(4):286-90. Abstract

James SK, Pieper KS, Cannon CP, Storey RF, Becker RC, Steg PG, Wallentin L, Harrington RA; PLATO study group. Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke. 2013;44:1477-9.

Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D, Maurer G, Morais J, Nicolau JC, Oto A, Storey RF, James SK, Cannon CP. Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study. Circulation. 2013;127:673-80. Abstract

Kohli, P., Udell, J. A., Murphy, S. A., Cannon, C. P., Antman, E. M., Braunwald, E., Wiviott, S. D. Discharge Aspirin Dose and Clinical Outcomes in Patients with Acute Coronary Syndromes treated with Prasugrel vs. Clopidogrel: An Analysis from the TRITON-TIMI 38 Study J Am Coll Cardiol. 2013;NA(NA):NA. Abstract

Kumbhani, D. J., Bavry, A. A., Desai, M. Y., Bangalore, S., Bhatt, D. L. Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: An updated meta-analysis of randomized trials J Am Coll Cardiol. 2013;NA(NA):NA. Abstract

Kunadian V, James SK, Wojdyla DM, Zorkun C, Wu J, Storey RF, Steg PG, Katus H, Emanuelsson H, Horrow J, Maya J, Wallentin L, Harrington RA, Gibson CM. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC Cardiovasc Interv. 2013;6:671-83. Abstract

Lopes, R. D., White, J. A., Atar, D., Keltai, M., Kleiman, N. S., White, H. D., Widimsky, P., Zeymer, U., Giugliano, R. P., Tricoci, P., Braunwald, E., Bode, C., Ohman, E. M., Armstrong, P. W., Newby, L. K. Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes Int J Cardiol. 2013;NA(NA):NA. Abstract

Matteau, A., Bhatt, D. L. Recent advances in antithrombotic therapy after acute coronary syndrome CMAJ. 2013;NA(NA):NA.

Mega, J. L., Braunwald, E. B., Murphy, S., Plotnikov, A, Cook-Bruns, N, Aylward, P., Chopra, V., Gao, R., Nicolau, J., Gibson, C. M., Timi Study Group Rivaroxaban in the Settling of continued Dual Antiplatelet Therapy: Findings from the ATLAS ACS 2 - TIMI 51 Trial Journal of the American College of Cardiology. 2013;61(10):A1.

Mega, J. L., Braunwald, E., Wiviott, S. D., Murphy, S. A., Plotnikov, A., Gotcheva, N., Ruda, M., Gibson, C. M. Comparison of the Efficacy and Safety of Two Rivaroxaban Doses in Acute Coronary Syndrome (from ATLAS ACS 2-TIMI 51) Am J Cardiol. 2013;NA(NA):NA. Abstract

Mogabgab, O., Wiviott, S. D., Cannon, C. P., Sloan, S., Sabatine, M. S., Antman, E. M., Braunwald, E., Giugliano, R. P. Circadian Variation of Stent Thrombosis and the Effect of More Robust Platelet Inhibition: A Post Hoc Analysis of the TRITON-TIMI 38 Trial J Cardiovasc Pharmacol Ther. 2013;NA(NA):NA. Abstract

Motiwala, S. R., Sarma, A., Januzzi, J. L., O'Donoghue, M. L. Biomarkers in ACS and Heart Failure: Should Men and Women Be Interpreted Differently? Clin Chem. 2013;NA(NA):NA. Abstract

Nazer, B., Ray, K. K., Murphy, S. A., Gibson, C. M., Cannon, C. P. Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy J Thromb Thrombolysis. 2013;36(3):233-9. Abstract

Nicholls, S. J., Kastelein, J. J., Schwartz, G. G., Bash, D., Rosenson, R. S., Cavender, M. A., Brennan, D. M., Koenig, W., Jukema, J. W., Nambi, V., Wright, R. S., Menon, V., Lincoff, A. M., Nissen, S. E., for the, Vista-Investigators Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome: The VISTA-16 Randomized Clinical Trial JAMA. 2013;NA(NA):NA. Abstract

O'Donoghue, Michelle L, Mega, Jessica L, Braunwald, Eugene, Nicolau, Jose C, Bhatt, Deepak L, Murphy, Sabina A, Gibson, C. Michael Abstract 11382: The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial Circulation. 2013;128(22 Supplement):A11382.

Ojeifo, O., Wiviott, S. D., Antman, E. M., Murphy, S. A., Udell, J. A., Bates, E. R., Mega, J. L., Sabatine, M. S., O'Donoghue, M. L. Concomitant Administration of Clopidogrel With Statins or Calcium Channel Blockers: Insights From the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38) Trial JACC Cardiovasc Interv. 2013;NA(NA):NA. Abstract

Peacock, W. F., Kontos, M. C., Amsterdam, E., Cannon, C. P., Diercks, D., Garvey, L., Graff, L. th, Holmes, D., Holmes, K. S., McCord, J., Newby, K., Roe, M., Dadkhah, S., Siler-Fisher, A., Ross, M. Impact of Society of Cardiovascular Patient Care accreditation on quality: an ACTION Registry(R)-Get With The Guidelines analysis Crit Pathw Cardiol. 2013;12(3):116-20. Abstract

Pride, Y. B., Piccirillo, B. J., Gibson, C. M. Prevalence, consequences, and implications for clinical trials of unrecognized myocardial infarction Am J Cardiol. 2013;111(6):914-8. Abstract

Ruff CT, Bonaca MP, Kosowsky JM, Conrad MJ, Murphy SA, Jarolim P, Donahoe SM, O'Donoghue ML, Morrow DA. Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study. J Thromb Thrombolysis. 2013;36:361-367. Abstract

Ruff CT, Bonaca MP, Kosowsky JM, Conrad MJ, Murphy SA, Jarolim P, Donahoe SM, O'Donoghue ML, Morrow DA. Erratum to: Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study. J Thromb Thrombolysis. 2013;36:368.

Smith, S. W., Diercks, D. B., Nagurney, J. T., Hollander, J. E., Miller, C. D., Schrock, J. W., Singer, A. J., Apple, F. S., McCullough, P. A., Ruff, C. T., Sesma, A., Jr., Peacock, W. F. Central versus local adjudication of myocardial infarction in a cardiac biomarker trial Am Heart J. 2013;165(3):273-279 e1. Abstract

Steen, Dylan L., Cannon, Christopher P., Lele, Suhas S., Rajapurkar, Mohan M., Mukhopadhyay, Banibrata, Scirica, Benjamin M., Murphy, Sabina A., Morrow, David A. Prognostic Evaluation of Catalytic Iron in Patients With Acute Coronary Syndromes Clinical Cardiology. 2013;NA(NA):n/a-n/a.

Tantry, U. S., Bonello, L., Aradi, D., Price, M. J., Jeong, Y. H., Angiolillo, D. J., Stone, G. W., Curzen, N., Geisler, T., Ten Berg, J., Kirtane, A., Siller-Matula, J., Mahla, E., Becker, R. C., Bhatt, D. L., Waksman, R., Rao, S. V., Alexopoulos, D., Marcucci, R., Reny, J. L., Trenk, D., Sibbing, D., Gurbel, P. A. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to ADP Associated with Ischemia and Bleeding J Am Coll Cardiol. 2013;NA(NA):NA. Abstract

Truong, Q. A., Hayden, D. L., Woodard, P. K., Kirby, R., Chou, E. T., Nagurney, J. T., Wiviott, S. D., Fleg, J. L., Schoenfeld, D. A., Udelson, J. E., Hoffmann, U. Sex Differences in the Effectiveness of Early Coronary CT Angiography Compared to Standard Emergency Department Evaluation for Acute Chest Pain: The ROMICAT II Trial Circulation. 2013;NA(NA):NA. Abstract

Udell, J. A., Morrow, D. A., Braunwald, E., Swedberg, K., Bode, C., Rifai, N., Brunel, P. C., Prescott, M. F., Ren, F., Hoffman, E. B., Scirica, B. M. Inhibition of the Renin-Angiotensin System Reduces the Rise in Serum Aldosterone in Acute Coronary Syndrome Patients with Preserved Left Ventricular Function: Observations from the AVANT GARDE-TIMI 43 Trial Clin Chem. 2013;NA(NA):NA. Abstract

Udell, Jacob A, Bhatt, Deepak L, Hoffman, Elaine B, Cannon, Christopher P Abstract 10286: Benefit of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes After Recent Influenza-like Illness: Results From the PROVE IT-TIMI 22 Trial Circulation. 2013;128(22 Supplement):A10286.

Bonaca MP, Bhatt DL, Braunwald E, Cohen M, Steg PG, Storey RF, Held P, Jensen EC, Sabatine MS Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J. 2014;167:437-444. Abstract

Bonaca, M. P., Murphy, S. A., Miller, D., Herrman, J. P., Gottlieb, S., Keltai, M., Menozzi, A., Nicolau, J. C., Widimsky, P., Antman, E. M., Wiviott, S. D. Patterns of Long-term Thienopyridine Therapy and Outcomes in Patients With Acute Coronary Syndrome Treated With Coronary Stenting: Observations From the TIMI-38 Coronary Stent Registry Clin Cardiol. 2014;NA(NA):NA. Abstract

Bui, An, Cannon, Christopher, Steg, Philippe, Storey, Robert, Husted, Steen, Ren, Fang, James, Stefan, Michelson, Eric, Himmelmann, Anders, Wallentin, Lars, Scirica, Benjamin RISK OF CARDIOVASCULAR DEATH AND NON-SUSTAINED VENTRICULAR TACHYCARDIA DETECTED 30-DAYS AFTER ACUTE CORONARY SYNDROME IN THE PLATO (PLATELET INHIBITION AND PATIENT OUTCOMES) TRIAL Journal of the American College of Cardiology. 2014;63(12, Supplement):A298.

Carreras, E. T., Mega, J. L. Dual antiplatelet therapy for heart disease Circulation. 2014;129(21):e506-8.

Gutierrez, A., Bhatt, D. L. Balancing the risks of stent thrombosis and major bleeding during primary percutaneous coronary intervention Eur Heart J. 2014;NA(NA):NA.

Mahaffey KW, Held C, Wojdyla DM, James SK, Katus HA, Husted S, Steg PG, Cannon CP, Becker RC, Storey RF, Khurmi NS, Nicolau JC, Yu CM, Ardissino D, Budaj A, Morais J, Montgomery D, Himmelmann A, Harrington RA, Wallentin L; PLATO Investigators. Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. J Am Coll Cardiol. 2014;63:1493-9. Abstract

O'Donoghue, M. L. Acute coronary syndromes: Targeting inflammation-what has the VISTA-16 trial taught us? Nat Rev Cardiol. 2014;11(3):130-2.

Sarma, A., Cannon, C. P., de Lemos, J., Rouleau, J. L., Lewis, E. F., Guo, J., Mega, J. L., Sabatine, M. S., O'Donoghue, M. L. The Incidence of Kidney Injury for Patients Treated With a High-Potency Versus Moderate-Potency Statin Regimen After an Acute Coronary Syndrome J Am Heart Assoc. 2014;3(3):e000784. Abstract

Sherwood, M. W., Wiviott, S. D., Peng, S. A., Roe, M. T., Delemos, J., Peterson, E. D., Wang, T. Y. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry J Am Heart Assoc. 2014;3(2):e000849. Abstract

Xu, Haiyan, Yang, YueJin, Yang, Jingang, Li, Wei, Peterson, Eric, Roe, Matthew, Xian, Ying, Sabatine, Marc, Wiviott, Stephen THE CHINA ACUTE MYOCARDIAL INFARCTION REGISTRY: A NATIONAL REGISTRY-QUALITY IMPROVEMENT INTEGRATED PROGRAM IN CHINA Journal of the American College of Cardiology. 2014;63(12, Supplement):A174.